ArticleClinical diabetes : a publication of the American Diabetes Association2018

Safety and Efficacy of Insulin Degludec/Liraglutide (IDegLira) and Insulin Glargine U100/Lixisenatide (iGlarLixi), Two Novel Co-Formulations of a Basal Insulin and a Glucagon-Like Peptide-1 Receptor Agonist, in Patients With Diabetes Not Adequately Controlled on Oral Antidiabetic Medications.

Carol H Wysham et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.